Reagents and instruments for immunology, cell biology and molecular biology.

Online webinar : Methylation Markers and Digital PCR: Advancing Precision Follow-Up for Cancer Patients

/upload/webinar-6-karab6.jpg

Live Webinar Invitation
Date: Tuesday, 14 April 2026 | Time: 11: 30 AM CET

Liquid biopsy has emerged as a minimally invasive approach for detecting and monitoring disease by analyzing biomarkers such as circulating tumor DNA (ctDNA). Digital PCR (dPCR) enables rapid, highly sensitive and precise quantification of low-abundance methylated ctDNA in biological fluids such as blood or urine.

This webinar will highlight the clinical application of methylation markers using digital PCR for the follow-up of cancer patients via liquid biopsy. It will demonstrate how these tools provide actionable insights for prognosis, tumor evolution monitoring, and early relapse detection in advanced cancers (stages III–IV), while effectively complementing existing NGS-based approaches.

Join Our Exclusive Live Webinar

Methylation Markers and Digital PCR for Cancer Patient Follow-Up
Presented by Dr. Valérie Taly, President & CSO, METHYS Dx

14 April 2026 • 11: 30 AM CET • Live Online via Zoom

This webinar is tailored for oncology researchers, clinicians, and professionals working with PCR-based methylation biomarkers and liquid biopsy technologies. Limited places available.

Overview

METHYS Dx develops innovative M*Detect kits that leverage proprietary methylation signatures for the analysis of circulating tumor DNA (ctDNA) in liquid biopsy samples. These kits are fully compatible with commercially available digital PCR instruments and deliver results within a single day. The technology offers a cost-effective, high-sensitivity alternative or complement to NGS workflows, enabling precise prognosis, real-time tumor burden monitoring, and early detection of relapse in patients with advanced cancers.

Attendees will explore how dPCR-based methylation analysis provides absolute quantification with superior sensitivity, supporting personalized oncology strategies and translational research.

Meet the Speaker

Dr. Valérie Taly, PhD

President & Chief Scientific Officer, METHYS Dx
CNRS Research Director (DR1), Translational Research and Microfluidics Group (MEPPOT team, Université Paris Cité)

Dr. Valérie Taly is a recognized pioneer in the development and clinical application of digital PCR (dPCR), particularly for liquid biopsy in oncology. Her expertise spans technology development, biomarker discovery, and diagnostic translation. She is co-inventor of 17 patents and author of more than 145 peer-reviewed publications. As co-founder of METHYS Dx, Dr. Taly has dedicated her career to advancing methylation-based biomarkers for non-invasive cancer monitoring. Her research, conducted in collaboration with leading clinical teams, has driven innovations that enable precise detection, prognostication, and real-time follow-up of tumor burden using methylated ctDNA.

Key Takeaways

Practical dPCR Applications

Understand how methylation markers combined with digital PCR deliver highly sensitive ctDNA analysis for cancer patient follow-up with results available in one day.

Clinical and Research Advantages

Discover the benefits of M*Detect kits for prognosis, tumor monitoring, and early relapse detection, including their role as a cost-effective complement to NGS in oncology workflows.

Implementation Strategies

Gain expert insights on integrating dPCR methylation biomarkers into your laboratory or clinical practice to enhance precision medicine approaches in oncology.

We look forward to your participation in this informative session on 14 April 2026 at 11: 30 AM CET. Registration is free but required to receive the joining link.